Rockwell Medical, Inc. (RMTI) vs SCYNEXIS, Inc. (SCYX)

Rockwell Medical, Inc. and SCYNEXIS, Inc. are both Drug Manufacturers Specialty & Generic companies. SCYNEXIS, Inc. is the larger, with a market value of $45.0M against $34.5M — 1.3× the size. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against −21.1%. Rockwell Medical, Inc. has the higher net margin (−7.33% vs −49.7%) and the higher return on invested capital (−14.6% vs −110.7%). Across the 18 metrics below, Rockwell Medical, Inc. leads on 10 and SCYNEXIS, Inc. on 8.

Valuation

Metric RMTI SCYX Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.48 2.52 2.25
P/B 0.95 0.78 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.25 1.15 2.56
Earnings yield (15.95%) (47.61%) (2.99%)
Free cash flow yield (2.95%) (25.67%) 0.00%

Profitability

Metric RMTI SCYX Drug Manufacturers Specialty & Generic median
Gross margin 17.71% 100.00% 53.94%
Operating margin (6.52%) (109.90%) 0.00%
Net margin (7.33%) (49.74%) 0.00%
Free cash flow margin 2.47% (64.67%) 0.00%
Return on equity (15.53%) (18.38%) (0.40%)
Return on assets (9.32%) (15.09%) (3.32%)
Return on invested capital (14.58%) (110.72%) 0.00%

Growth

Metric RMTI SCYX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (21.12%) 682.47% 10.01%
EPS growth (last fiscal year) (870.87%) 61.36% —
Revenue growth, 5-year CAGR 2.17% 179.40% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RMTI SCYX Drug Manufacturers Specialty & Generic median
Debt to equity 0.26 0.00 0.05
Current ratio 3.25 9.65 2.31
Net debt to EBITDA 7.40 2.54 0.85

Dividend

Metric RMTI SCYX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric RMTI SCYX Drug Manufacturers Specialty & Generic median
Market cap 34.54m 44.98m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack